CN119403831A - 包含nrp1结合结构域的双特异性抗体及其使用方法 - Google Patents

包含nrp1结合结构域的双特异性抗体及其使用方法 Download PDF

Info

Publication number
CN119403831A
CN119403831A CN202380044206.1A CN202380044206A CN119403831A CN 119403831 A CN119403831 A CN 119403831A CN 202380044206 A CN202380044206 A CN 202380044206A CN 119403831 A CN119403831 A CN 119403831A
Authority
CN
China
Prior art keywords
seq
sequence shown
bispecific antibody
domain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380044206.1A
Other languages
English (en)
Chinese (zh)
Inventor
H-J·宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pine Tree Treatment Co
Original Assignee
Pine Tree Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pine Tree Treatment Co filed Critical Pine Tree Treatment Co
Publication of CN119403831A publication Critical patent/CN119403831A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202380044206.1A 2022-03-30 2023-03-30 包含nrp1结合结构域的双特异性抗体及其使用方法 Pending CN119403831A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
US63/325312 2022-03-30
US63/325317 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Publications (1)

Publication Number Publication Date
CN119403831A true CN119403831A (zh) 2025-02-07

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380044206.1A Pending CN119403831A (zh) 2022-03-30 2023-03-30 包含nrp1结合结构域的双特异性抗体及其使用方法

Country Status (13)

Country Link
US (1) US20240101682A1 (https=)
EP (1) EP4499696A1 (https=)
JP (1) JP2025511135A (https=)
KR (1) KR20240163751A (https=)
CN (1) CN119403831A (https=)
AU (1) AU2023245728A1 (https=)
CA (1) CA3255754A1 (https=)
CL (1) CL2024002899A1 (https=)
CO (1) CO2024014799A2 (https=)
CR (1) CR20240462A (https=)
IL (1) IL315960A (https=)
MX (1) MX2024011978A (https=)
WO (1) WO2023192514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318499A (en) * 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
AU2023378712A1 (en) * 2022-11-07 2025-05-01 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) * 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
CA3060190A1 (en) * 2017-04-24 2018-11-01 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Also Published As

Publication number Publication date
KR20240163751A (ko) 2024-11-19
CL2024002899A1 (es) 2025-02-07
US20240101682A1 (en) 2024-03-28
CA3255754A1 (en) 2023-10-05
JP2025511135A (ja) 2025-04-15
EP4499696A1 (en) 2025-02-05
AU2023245728A1 (en) 2024-09-26
WO2023192514A1 (en) 2023-10-05
CO2024014799A2 (es) 2024-11-18
IL315960A (en) 2024-11-01
CR20240462A (es) 2024-12-11
MX2024011978A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
TWI840386B (zh) 抗間皮素抗體
EP3345928B1 (en) Human cd3 binding antibody
JP6524087B2 (ja) Ｃｄ１２３及びｃｄ３に結合できる二重特異性１価ダイアボディ、並びにその使用
JP2025102836A (ja) 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用
KR20210030925A (ko) 메소텔린 및 cd137 결합 분자
WO2019047885A1 (en) IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
CN119403831A (zh) 包含nrp1结合结构域的双特异性抗体及其使用方法
JP2025098135A (ja) Ｐｄ－１ポリペプチド変異体
JP2024509501A (ja) 新規活性を持つｈｈｌａ２結合剤
JP2024534041A (ja) インターロイキン－１２バリアント及び使用方法
KR20250044738A (ko) 표적화 라이소좀 분해를 위한 조성물 및 이의 사용 방법
JP7304815B2 (ja) Ｅｒｂｂ－２、ｅｒｂｂ－２／ｅｒｂｂ－３陽性腫瘍を有する個体の処置のための、ｅｒｂ－２及びｅｒｂｂ－３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ－２標的化剤及び二重特異性抗体
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
TW202400650A (zh) 抗體與cd47抑制劑之組合
JP7371093B2 (ja) 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ
EA052797B1 (ru) Биспецифичные антитела, содержащие домен, связывающий nrp1, и способы их применения
CN121568963A (zh) 用于靶向溶酶体降解的非受体酪氨酸激酶组合物及其使用方法
TW202434631A (zh) 抗il-2抗體之使用方法
TW202542201A (zh) 抗psma軛合物及其使用方法
HK40113788A (zh) 抗cd39抗体及其用途
EA052461B1 (ru) Агент, нацеленный на erbb-2, и биспецифическое антитело с сайтами связывания антигена, которые связывают эпитоп на внеклеточной части erbb-2 и erbb-3, для лечения индивида с положительной по erbb-2, erbb-3 или erbb-2/3 опухолью

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination